NCT05864612 is a NA clinical trial of Screening Questionnaires in Epilepsy, sponsored by Wake Forest University Health Sciences.

Who is sponsoring NCT05864612?

NCT05864612 is sponsored by Wake Forest University Health Sciences.

What drugs are being tested in NCT05864612?

Interventions in NCT05864612: Screening Questionnaires.

Is NCT05864612 still recruiting?

NCT05864612 is currently completed. Last updated 30 October 2025.

Are results published for NCT05864612?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-10-30 · How we verify

NCT05864612

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tools for Anxiety and Depression Screening in Epilepsy

Completed NA Results posted Last updated 30 October 2025

What this trial tests

NA trial testing Screening Questionnaires in Epilepsy in 880 participants. Completed in 3 September 2024.

Timeline

20 September 2023

Primary endpoint
3 September 2024

3 September 2024

Quick facts

Lead sponsor	Wake Forest University Health Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	880
Start date	20 September 2023
Primary completion	3 September 2024
Estimated completion	3 September 2024
Sites	1 location across United States

Drugs / interventions tested

Screening Questionnaires

Conditions studied

Epilepsy — all drugs for Epilepsy →

Sponsor

Wake Forest University Health Sciences

Who can join

18 and older, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Subjects Completing Screening Instruments Primary · Week 1

Percentage of subjects completing screening instruments by each of the 4 methods prior to clinic visit will be used to compare the effect of the different methods on patient self-completion, and to estimate completion rates by different methods for use in future screening implementation trials.

Group	Value	95% CI
Text Message	0
Customized Email Prompt	14
Generic Electronic Health Record (EHR) Portal Email	19
EHR Portal With No Message	12

Research Team Time-sending Instruments Secondary · Baseline Day 0

Time in minutes will be recorded

Group	Value	95% CI
Text Message	3.0	± 1.6
Customized Email Prompt	4.5	± 1.8
Generic Electronic Health Record (EHR) Portal Email	1.7	± 1.2
EHR Portal With No Message	0.6	± 0.6

Research Team Time-instrument Data Entry Secondary · Week 1

Time in minutes will be recorded

Group	Value	95% CI
Customized Email Prompt	2.5	± 2.0
Generic Electronic Health Record (EHR) Portal Email	1.8	± 2.0
EHR Portal With No Message	1.7	± 2.4

Participant Time From Instrument Delivery to Completion Secondary · Week 1

Time in minutes will be recorded

Group	Value	95% CI
Customized Email Prompt	4.6	± 2.4
Generic Electronic Health Record (EHR) Portal Email	3.1	± 2.6
EHR Portal With No Message	2.2	± 2.1

Percent Accuracy of Kit Application Programming Interface (API) Secondary · Week 1

Among participants who completed anxiety and depression screening instruments by one of the two EHR methods, this measure evaluates the % of instrument scores collected via Kit API that were identical to the original EHR source completion.

Group	Value	95% CI
Generic Electronic Health Record (EHR) Portal Email	100	100 – 100
EHR Portal With No Message	100	100 – 100

Sponsor's own description

A randomized trial to compare patient-completion success of REDCap and Electronic Health Record (EHR)-based anxiety \& depression instrument delivery methods. Study hypothesis is that the screening completion proportion will vary across the 4 modalities tested.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other Wake Forest University Health Sciences trials

Trials by the same sponsor.

NCT07474090 — Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial · NA · not yet recruiting
NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
NCT06876896 — Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter · NA · recruiting
NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
NCT07215624 — Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05864612 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wake Forest University Health Sciences
Last refreshed: 30 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05864612.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT05864612

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of Screening Questionnaires

Other recruiting trials for Epilepsy

Other Wake Forest University Health Sciences trials

Verify against primary sources